Opko Health, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
OPKO Health, Inc. reported a significantly wider net loss of $225.7 million in 2025, despite an improved operating loss and strategic divestitures aimed at streamlining its diagnostics business.
NASDAQ
OPKO Health files an amendment to its 2024 annual report to correct an exhibit and include XBRL tagging.
NASDAQ
10-K: OPKO Health's 2024 10-K Filing: Strategic Realignment and Continued Investment in Growth Pipeline
OPKO Health's 2024 10-K filing highlights strategic moves including asset sales and pipeline advancements amidst ongoing financial challenges.
NASDAQ
OPKO Health's 2023 10-K filing details financial performance, product updates, and strategic initiatives across its pharmaceutical and diagnostics segments.